Campbell & Co Investment Adviser’s SpringWorks Therapeutics SWTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,918	Closed	-$482K	–	1455
2025 Q1	$482K	Sell	10,918 -16,966	-61%	-$781K	0.04%	691
2024 Q4	$1.01M	Buy	27,884 +14,411	+107%	+$504K	0.08%	393
2024 Q3	$432K	Buy	+13,473	New	+$503K	0.03%	770
2024 Q2	–	Sell	-16,644	Closed	-$819K	–	1343
2024 Q1	$819K	Buy	16,644 +3,322	+25%	+$154K	0.07%	478
2023 Q4	$486K	Buy	+13,322	New	+$348K	0.04%	728

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Campbell & Co Investment Adviser's SWTX Position: Q2 2025 in Review

Campbell & Co Investment Adviser sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 10,918 shares — an estimated $482K sold.

Campbell & Co Investment Adviser first reported a position in SWTX in Q4 2023 and held it in 5 quarters. The position peaked at $1.01M in Q4 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Campbell & Co Investment Adviser reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 10,918 SpringWorks Therapeutics shares in Q2 2025, an estimated $482K.
Campbell & Co Investment Adviser first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 5 quarters.
Campbell & Co Investment Adviser's SpringWorks Therapeutics position peaked at $1.01M in Q4 2024.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2025, filed 7 Aug 2025.